MVA85A

From Wikipedia, the free encyclopedia

MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the old TB vaccine called BCG.[1] Phase I clinical trials have been completed and phase II clinical trials are currently underway in South Africa with the aim of achieving a product licence by 2010.[2]

[edit] External links

[edit] References

  1. ^ McShane H, Pathan AA, Sander CR, et al. (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-microbial immunity in humans". Nat Med 10: 1240–44. 
  2. ^ Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H (2006). "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design". Lancet Infect Dis 6 (8): 522-8. doi:10.1016/S1473-3099(06)70552-7. PMID 16870530. 
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.